Actively Recruiting

All Genders
NCT03358693

Molecular Signatures in Inflammatory Skin Disease

Led by Prof. Dr. Stephan Weidinger · Updated on 2025-07-22

300

Participants Needed

1

Research Sites

675 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This pilot project intends to examine the utility of a systems medicine approach to identify regulatory networks and their perturbation in psoriasis and atopic dermatitis, and to obtain a comprehensive perspective on disease and disease control by integrating and modelling data across multiple cellular levels and time following specific blockade of single pathophysiological factors through use of licensed biologics during routine care as systems biology challenge. To this end, ultra-deep phenotyping and prospective molecular characterization in short time-intervals and different disease equilibrium states will be carried out in targeted small sets of patients. The different layers and types of clinical and molecular information will then be integrated (integrative personal omics profiling iPOP) for generating insights into disease pathways and for extraction of molecular signatures that correspond to clinical severity scores. It will provide a good starting point for planning future trials aimed at identifying biological patterns useful for guiding targeted treatment.

CONDITIONS

Official Title

Molecular Signatures in Inflammatory Skin Disease

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Ability to provide written informed consent and comply with the protocol
  • Dermatologist-diagnosed chronic inflammatory skin disease
  • Subject receives systemic therapy within routine care (in-label use of biologics)
Not Eligible

You will not qualify if you...

  • Unable to provide written informed consent or comply with the protocol
  • Use of immunosuppressive or immunomodulating therapy or phototherapy within 4 weeks before baseline visit
  • Treatment of selected skin areas to be examined with topical corticosteroid or topical calcineurin inhibitor within 1 week before baseline visit

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Department of Dermatology, University Hospital Schleswig Holstein, Campus Kiel

Kiel, Germany, 24105

Actively Recruiting

Loading map...

Research Team

S

Stephan Weidinger, MD

CONTACT

S

Sascha Gerdes, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

13

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here